Premium
Radiosynthesis of the HIV integrase inhibitor [ 18 F]MK‐0518 (Isentress)
Author(s) -
Li Wenping,
Thompson Wayne,
Fisher Thorsten,
Wai John S.,
Hazuda Daria,
Burns H. Donald,
Hamill Terence G.
Publication year - 2010
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.1778
Subject(s) - chemistry , radiosynthesis , integrase , trifluoromethanesulfonate , yield (engineering) , radiochemistry , organic chemistry , positron emission tomography , catalysis , biochemistry , nuclear medicine , medicine , materials science , metallurgy , gene
The human immunodeficiency virus integrase inhibitor, [ 18 F]MK‐0518, was prepared via a three‐step, one‐pot radiosynthesis. [ 18 F]4‐Fluorobenzylamine was produced from the fluorination of 4‐cyano‐ N , N , N ‐trimethylammonium triflate with [ 18 F]fluoride and reduction with borane methylsulfide complex in 50–68% radiochemical yield. The final step, the coupling of [ 18 F]4‐fluorobenzylamine with an ester coupling partner, achieved an overall uncorrected radiochemical yield after HPLC purification of ∼2%, based on the starting [ 18 F]fluoride. In a typical run, the total synthesis time was about 90 min and gave 0.37–1.74 GBq (10–47 mCi) of [ 18 F]MK‐0518. The radiochemical purity of [ 18 F]MK‐0518 was>98% and the specific activity was 243–1275 Ci/mmol (EOS, n =4). A convenient three‐step, one‐pot radiosynthesis of [ 18 F]MK‐0518 via [ 18 F]4‐fluorobenzylamine has been developed, giving sufficient quantities of [ 18 F]MK‐0518 for animal positron emission tomography studies. Copyright © 2010 John Wiley & Sons, Ltd.